【摘要】 目的　评估口服 15 0mg米非司酮及 30 0mg米非司酮在足月妊娠中促宫颈成熟效果及对新生儿的安全性观察。方法　 2 5 0位宫颈Bishop评分≤ 5分的初产妇 ,随机分为三个治疗组 ,观察其服药前后的宫颈Bishop评分改变及产科结局。结果　 15 0mg组及 30 0mg组均具有有效的促宫颈成熟作用 ,15 0mg组胎儿宫内窘迫发生率为 12 % ,合并胎儿宫内窘迫而剖宫产者 2 8.5 7% (10 / 35 )。 30 0mg组胎儿宫内窘迫发生率为 2 3 % ,合并胎儿宫内窘迫而剖宫产者 5 2 .6 3 % (2 0 / 38)。两组间有显著性差异 (P <0 .0 5 )。结论　米非司酮为受体水平的抗孕激素 ,它可软化宫颈、提高子宫的活性。在本研究中 15 0mg组米非司酮具有有效的促宫颈成熟作用 ,且胎儿宫内窘迫发生率相对较低更多还原

【Abstract】 Objectives To compare the effectiveness and safety of 150 mg and 300 mg oral mifepristone on cervical ripening of primigravidae.Methods 250 primigravidae at term with a Bishop score of 5 or less were randomly assigned to one of the three treatment groups, and to observe the alterations in Bishop score after oral Mifepristone and the outcomes of pregnancy. Results 150 mg and 300 mg oral mifepristone could improve cervical ripening. In the group treated with 300 mg mifepristone, the rate of fetal distress was 23% and rate of cesarean section was 52.63%(20/38). While in the group treated with 150 mg mifepristone, the rate of fetal distress was 12% and rate of cesarean section was 28.57%(10/35). Conclusions Mifepristone, a progesterone antagonist, is known to cause softening and dilation of the early pregnant cervix and increase in uterine activity. In this study, 150 mg of mifepristone improves the cervical ripening and causes lower rate of fetal distress. (Shanghai Med J, 2000,23∶486 488)更多还原